Orbital Manufacturing Scaling Up: Varda Secures $251M Series D
Varda Space Industries has closed a major $251M funding round, valuing the company at $1.6B as it prepares to scale its off-world pharmaceutical and semiconductor manufacturing operations.
Varda Capital Injection: Scaling High-G Processing
Varda has finalized a $251 million Series D funding round to industrialize its orbital manufacturing platform. According to Payload, the round was co-led by Lux Capital and Natural Capital, pushing Varda’s total capital raised to nearly $600 million and establishing a post-money valuation of $1.6 billion. A roster of high-profile backers including Founders Fund, Khosla Ventures, and General Catalyst also participated.
The Microgravity Advantage
The core of Varda’s business model centers on the unique physics of the orbital environment. In sustained low gravity, pharmaceutical ingredients crystallize in ways unachievable on the terrestrial surface, potentially yielding more potent or stable medical compounds. Beyond biology, the company’s re-entry capsules serve semiconductor manufacturers seeking superior material structures and national security agencies requiring hypersonic testing environments.
Mission Status: W-8 and W-9 Active
With six re-entry missions already completed, Varda is accelerating its operational tempo. Over a dozen missions are projected for the next 24 months. Immediate attention is focused on the W-8 and W-9 capsules, scheduled for deployment via SpaceX’s Transporter-18 mission as early as this Thursday.
- W-8: Optimized for thermal data collection, testing external protection materials under a U.S. military study.
- W-9: A Department of Defense-integrated mission focused on hypersonic navigation and advanced heat shield tiles supplied by Syensqo.
This capital influx ensures the infrastructure is in place to transition from experimental flights to a persistent, revenue-generating orbital supply chain.